Navigation Links
Study shows major pain research funding decline at NIH
Date:12/11/2008

GLENVIEW, IL, Dec. 11, 2008 Federal funding for pain research is declining sharply, more than 9 percent a year since 2003, according to a new study published in The Journal of Pain. Pain research, as a result, now accounts for only 0.6 percent of all grants awarded by the National Institutes of Health (NIH), despite the high prevalence of chronic pain in the U.S.

"This startling finding shows the government's meager investment in pain research is seriously out of proportion with the widespread chronic pain incidence in our society, which is estimated at one in four Americans and accounts for more than 20 percent of all physician office visits," said Charles E. Inturrisi, president of the American Pain Society and professor of pharmacology at Weill Cornell Medical College, New York. "And this disparity is not attributable to years of budget cuts at NIH because the Journal of Pain study clearly shows pain research has a higher percentage decline than the overall NIH budget. So the drop in agency funding has not affected all research areas equally."

University of Utah researchers led by David H. Bradshaw, PhD of the university's pain research center, analyzed data about NIH grant awards from 2003 through 2007 for pain and compared pain research funding with dollars allocated for nausea and dyspnea, a breathing disorder. A previous study authored by Bradshaw, also published in The Journal of Pain in 2005, found that less than one percent of all NIH funding in 2003 was for research having a primary emphasis on pain. The current study shows that five years later pain research is still a low priority at NIH.

Noting that overall budget pressures in Washington have led to an unprecedented recession in funding for biomedical research, the authors said: "With decreased funding for research and continuing needs for resources to support national security and military efforts, major natural disasters and uncertain economic status, competition for limited research funds will intensify. The ability to track funding patterns becomes increasingly important for policy making decisions."

Inturrisi said APS has given financial support for the group's ongoing monitoring of NIH funding for pain research. "Our goal is to provide policy makers with an objective and verifiable classification tool for measuring grant awards and funding trends to help determine if NIH research dollars are being directed where the scientific and clinical need is most compelling," said Inturrisi. "Untreated and undertreated pain is the nation's most pervasive health problem and it's getting worse as the population ages. Pain research is the key for learning more about pain mechanisms and possible new treatments, but it is difficult to make significant progress if pain studies comprise just half of one percent of all NIH research grants," he added.

The study also reported that a review of all records for primary research for nausea and dyspnea, revealed that, unlike pain research funding trends, grants for those conditions increased steadily from 2003 to 2007. The authors concluded that even though there have been unprecedented funding cuts at NIH, "additional measures should be taken at NIH to improve the chances of funding for meritorious applications proposing research on pain."


'/>"/>

Contact: Chuck Weber
cpweber@weberpr.com
847-705-1802
American Pain Society
Source:Eurekalert

Related medicine news :

1. Womens magazines downplay emotional health risks of cosmetic surgery: UBC study
2. Study Asks: Are Physicians Overusing an Invasive Cardiac Treatment?
3. Study Questions Value of Anti-Meth Campaign
4. U.S. Department of Education Funded Study Demonstrates, WordWorld, a PBS KIDS(R) Television Series Works as Critical Early Literacy Tool
5. Success of anti-meth ads questioned by study
6. Study first to show that RNA interference can facilitate vaccine development
7. Study Suggests Sugar May Be Addictive
8. UC San Diego scientists developing brain imaging methods for studying natural human behavior
9. Study Showed New Episodes of Depression Delayed in People Taking Cymbalta(R)
10. Study finds selenium, vitamin E do not prevent prostate cancer
11. Study Finds Doctors Use of E-Prescribing Systems Linked to Formulary Data Can Boost Drug Cost Savings
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... ... 2016 , ... Since launching its annual volunteer campaign on ... footwear industry, has broken all previous participation records in its first two weeks ... during the months of April and May, the 2016 Footwear Cares initiative is ...
(Date:4/29/2016)... ... April 29, 2016 , ... Our bodies are bombarded daily by ... and deal with these stressors is to adopt a more healthful diet, but too ... Risa Groux, a certified Holistic Nutritionist and the creator of the Newport Beach Cleanse ...
(Date:4/29/2016)... CA (PRWEB) , ... April 29, 2016 , ... ... advocating optimistic healthcare awareness and author of best seller "LOVE, MEDICINE and MIRACLES") ... Radio Monday, May 2, 2016 and podcasted thereafter . Dr. Bernie Siegel, ...
(Date:4/29/2016)... Fort Stewart, GA (PRWEB) , ... April 29, 2016 , ... ... on Monday, May 16, 2016, at its new location in the Exchange Furniture Mall ... including a raffle for a 50-inch Samsung Smart TV. Plus attendees will have the ...
(Date:4/29/2016)... ... April 29, 2016 , ... ... team BioCellection won the $30,000 Perlman Grand Prize of the 2016 Wharton Business ... Award, the Michelson People’s Choice Award, and the Committee Award for Most ‘Wow ...
Breaking Medicine News(10 mins):
(Date:4/27/2016)... Schweiz, April 27, 2016 ... CEO Forums in Zürich gab Strekin AG ... Wirkstoffkandidaten STR001 zur Erhaltung des Resthörvermögens von ... bekannt. Für die umfassende Phase-II-Doppelblindstudie mit Placebo-Kontrollgruppe ... angeworben. STR001 wird während der Operation direkt ...
(Date:4/27/2016)... , April 27, 2016   Zillion ... its digital health technology platform, which specializes in ... programs into scalable digital products, Zillion enables companies ... and empower consumers to take control of their ... live video conferencing – including one-to-one, group and ...
(Date:4/27/2016)... 2016 Oasmia Pharmaceutical AB ... a new generation of drugs within human and ... for Paclical/Apealea in the Phase III study that ... ovarian cancer. These preliminary results showed non-inferiority between ... carboplatin versus Taxol in combination with carboplatin. In ...
Breaking Medicine Technology: